Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces agreement with Mylan

Pfizer announces agreement with Mylan

15th October 2009

Pfizer has revealed that it has come to an agreement with Mylan concerning the antifungal agent Vfend (voriconazole).

The firm will work with two of Mylan’s subsidiaries to establish a settlement and license agreement for a generic version of the treatment.

Collaboration between the three organisations will focus on the tablet form of the antifungal agent Vfend only and does not cover Pfizer’s Vfend products for intravenous use or oral suspension.

Under the terms of the agreement, Mylan will reserve the rights to market voriconazole tablets during the first quarter of 2011, although other details of the partnership have not yet been disclosed.

It is also subject to the approval of the department of justice and the federal trade commission.

Last week, Pfizer revealed that the Antiviral Drugs Advisory Committee of the Food and Drug Administration voted ten to four to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naive adult patients with the CCR5-tropic HIV-1 virus, as part of combination therapy.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.